Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model

Human Gene Therapy

Volumn 7, Issue 14, 1996, Pages 1683-1691

  Ko, Song Chu ^a   Gotoh, Akinobu ^a   Thalmann, George N ^a   Zhau, Haiyen E ^a   Johnston, Dennis A ^a   Zhang, Wei Wei ^a,b   Kao, Chinghai ^a   Chung, Leland W K ^a,c  

^a UNIVERSITY OF TEXAS   (United States)

^b BAXTER HEALTHCARE CORPORATION   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53;

ADENOVIRUS; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL GROWTH; CONTROLLED STUDY; DNA SYNTHESIS; EXPRESSION VECTOR; GENE DELETION; GENE MUTATION; GENE THERAPY; METASTASIS; NONHUMAN; POINT MUTATION; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALIA; CUCUMBER MOSAIC VIRUS; MUS MUSCULUS;

EID: 0029818270     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1996.7.14-1683     Document Type: Article

References (35)

1. BAKER, S.J., MARKOWITZ, S., FEARSON, E.R., WILSON, J.K., and VOGELSTEIN, B. (1990). Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249, 912-915.
2. BARGONETTI, J., FRIEDMAN, P.N., KERN, S.E., VOGELSTEIN, B., and PRIVES, C. (1991). Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell 65, 1083-1091.
3. BERKNER, K.L. (1988). Development of adenovirus vectors for the expression of heterologous genes. Biotechniques 6, 616-629.
4. BORING, C.C., SQUIRES, T.S., TONG, T., and MONTGOMERY, S. (1994). Cancer statistics, 1994. CA Cancer J. Clin. 44, 7-26.
5. BOSHART, M., WEBER, F., JAHN, G., DORSCH-HASLER, K., FLECKENSTEIN, B., and SCHAFFNER, W. (1985). A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. Cell 41, 521-530.
6. CHENG, J., YEE, J.K., YEARGIN, J., FRIEDMAN, T., and HASS, M. (1992). Suppression of acute lymphoblastic leukemia by the human wild-type p53 gene. Cancer Res. 53, 222-226.
7. CLAYMAN, G.L., EL-NAGGAR, A.K., ROTH, J.A., ZHANG, W.-W., GOEPFERT, H., TAYLOR, D.L., and LIU, T.J. (1995). In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res. 55, 1-6.
8. DAMERON, K., VOPERT, O.V., TAINSKY, M.A., and BOUCK, N. (1994). Control of angiogenesis in fibroblast by p53 regulation of thrombospondin I. Science 265, 1582-1584.
9. DINJENS, W.N., VAN DER WEIDEN, M.M., SCHROEDER, F.H., and TRAPMAN, J. (1994). Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer. Int. J. Cancer 56, 630-633.
10. FARMER, G.E., BARGONETTI, J., ZHU, H., FRIEDMAN, P., PRYWES, R., and PRIVES, C. (1992). Wild-type p53 activates transcription in vitro. Nature 358, 42-46.
11. FINLAY, C.A., HINDS, P.W., and LEVINE, A.J. (1989). The p53 proto-oncogene can act as a suppressor of transformation. Cell 57, 1083-1093.
12. FRIEDMAN, T. (1989). Progress toward gene therapy. Science 244, 1275-1281.
13. FUJIWARA, T., GRIMM, E.A., MUKHOPADHYAY, T., ZHANG, W.-W., OWEN-SCHAUB, L.B., and ROTH, J.A. (1994). Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res. 54, 2287-2291.
14. GLEAVE, M., HSIEH, J.T., VON ESCHENBACH, A.C., and CHUNG, L.W.K. (1991). Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res. 51, 3753.
15. HEIDENBERG, H.B., SESTERHENN, I.A., GADDIPATI, J.P., WEGHORST, C.M., BUZARD, G.S., MOUL, J.W., and SRIVASTAVA, S. (1995). Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J. Urol. 154, 414-121.
16. HOUBIERS, J.G.A., NIJMAN, H.W., VAN DER BURG, S.H., DRIJFHOUT, J.W., KENEMANS, P., VAN DE VELDE, C.J.H., BRAND, A., MOMBURG, F., KAST, W.M., and MELIEF, C.J.M. (1993). In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur. J. Immunol. 23, 2072-2077.
17. HUGGINS, C., and HODGES, C.V. (1941). Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on the normal and on the hyperplastic prostate glands of dogs. Cancer Res. 1, 293.
18. ISSACS, W.B., CARTER, B.S., and EWING, C.M. (1991). Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res. 51, 4716-4720.
19. MERCER, W.E. (1992). Cell cycle regulation and the p53 tumor suppressor protein. Crit. Rev. Eukaryotic Gene Expression 2, 251-263.
20. NOGUCHI, Y., CHEN, Y.-T., and OLD, L.J. (1994). A mouse mutant p53 product recognized by CD4+ and CD8+ T cells. Proc. Nat. Acad. Sci. USA 91, 3171-3175.
21. PARDOLL, D. (1992). Immunotherapy with cytokine gene-transduced tumor. Curr. Opin. Oncol. 4, 1124-1129.
22. SANDA, M.G., RESTIFO, N.P., WALSH, J.C., KAWAKAMI, Y., NELSON, W.G., PARDOLL, D.M., and SIMONS, J.W. (1995). Molecular characterization of defective antigen processing in human prostate cancer. J. Natl. Cancer Inst. 87, 280-285.
23. SRIVASTAVA, S., KATAYOSE, D., TONG, Y.O., CRAIG, C.R., MCLEOD, D.G., MOUL, J.W., COWN, K.H., and SETH, P. (1995). Recombinant adenovirus vector expressing wild-type p53 is a potent inhibitor of prostate cancer cell proliferation. Urology 46, 843-848.
24. TAKAHASHI, T., CARBONE, D., TAKAHASHI, T., NAU, M.M., HIDA, T., LINNOILA, I., UEDA, R., and MINNA, J.D. (1992). Wild-type but not mutant p53 suppresses the growth of human lung cancers bearing multiple genetic lesions. Cancer Res. 52, 2340-2343.
25. THALMANN, G.N., ANEZINIS, P.E., CHANG, S.M., ZHAU, H.E., KIM, E.E., HOPWOOD, V.L., PATHAK, S., VON ESCHENBACH, A.C., and CHUNG, L.W.K. (1994). Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res. 54, 2577-2581.
26. TOMINAGA, O., HAMELIN, R., REMVIKOS, Y., SALMON, R.J., and THOMAS, G. (1992). p53 from basic research to clinical implications. Crit. Rev. Oncol. 3, 257-282.
27. VOELLER, H.J., SUGARS, L.Y., PRETLOW, T., and GELMANN, E. (1994). p53 Oncogene mutations in human prostate cancer specimens. J. Urol. 151, 492-495.
28. WANG, J., BUCANA, C.D., ROTH, J.A., and ZHANG, W.W. Apoptosis induced in human osteosarcoma cells is one of the mechanisms for the cytocidal effect of Ad5CMV-p53. Cancer Gene Ther. 2, 9-17.
29. WEINBERG, R.A. (1991). Tumor suppressor genes. Science 254, 1138-1146.
30. WILCOCK, D., and LANE, D.P. (1991). Localization of p53, retinoblastoma and host replication proteins at sites of viral replication in herpes-infected cells. Nature 349, 429-431.
31. WU, H.C., HSIEH, J.T., GLEAVE, M.E., BROWN, N.M., PATHAK, S., and CHUNG, L.W.K. (1994). Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: Role of bone stromal cells. Int. J. Cancer 57, 406-412.
32. YANG, C., CIRIELLI, C., CAPOGROSSI, M.C., and PASSANITI, A. (1995). Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostate tumor cells. Cancer Res. 55, 4210-4213.
33. YANUCK, M., CARBONE, D.P., PENDLETON, C.D., TSUKUI, T., WINTER, S.F., MINNA, J.D., and BERZOFSKY, J.A. (1993). A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T cells. Cancer Res. 53, 3257-3261.
34. ZHANG, W.W., FANG, X., BRANCH, C.D., MAZUR, W., FRENCH, B.A., and ROTH, J.A. (1993). Generation and identification of recombinant adenovirus by liposome-mediated transfection and PCR analysis. Biotechniques 15, 868-872.
35. ZHANG, W.-W., FANG, X., MAZUR, W., FRENCH, B.A., GEORGES, R.N., and ROTH, J.A. (1994). High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant vectors. Cancer Gene Ther. 1, 5-13.